Disease on EC 3.2.1.117 - amygdalin beta-glucosidase
Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Acquired Immunodeficiency Syndrome
Computer-aided molecular design of novel glucosidase inhibitors for AIDS treatment.
amygdalin beta-glucosidase deficiency
Alpha glucosidases in white blood cells, with reference to the detection of acid alpha 1-4 glucosidase deficiency.
amygdalin beta-glucosidase deficiency
Diagnosing Gaucher disease: an on-going need for increased awareness amongst haematologists.
amygdalin beta-glucosidase deficiency
Extensive genetic heterogeneity in patients with acid alpha glucosidase deficiency as detected by abnormalities of DNA and mRNA.
amygdalin beta-glucosidase deficiency
Late familial pseudo-myopathic muscular glycogenosis with alpha 1,4 glucosidase deficiency. Morphological, histoenzymological and biochemical approach.
amygdalin beta-glucosidase deficiency
Molecular features of 23 patients with glycogen storage disease type III in Turkey: a novel mutation p.R1147G associated with isolated glucosidase deficiency, along with 9 AGL mutations.
amygdalin beta-glucosidase deficiency
The brain in late-onset glycogenosis II: a structural and functional MRI study.
amygdalin beta-glucosidase deficiency
White blood cells and the diagnosis of alpha-glucosidase deficiency.
amygdalin beta-glucosidase deficiency
[Chronic respiratory failure in a case with juvenile-onset acid alpha-glucosidase deficiency; successful therapy with nasal intermittent positive pressure ventilation (NIPPV)]
amygdalin beta-glucosidase deficiency
[Ichthyosiform scaling in alpha-1,4-glucosidase deficiency]
Atherosclerosis
Influence of acarbose (a glucosidase inhibitor) on experimental atherosclerosis in the rabbit.
Azoospermia
Seminal plasma hexosaminidase in patients with normal and abnormal spermograms.
Bronchopneumonia
A severe form of non-classic Pompe's disease with normal creatinine kinase level.
Cardiovascular Diseases
Functional Foods and Nutraceuticals as Dietary Intervention in Chronic Diseases; Novel Perspectives for Health Promotion and Disease Prevention.
Colonic Neoplasms
Ataxin-10 is part of a cachexokine cocktail triggering cardiac metabolic dysfunction in cancer cachexia.
Connective Tissue Diseases
Excretion of glucose-containing oligosaccharides in urines of orthopedic patients.
COVID-19
Role of Drugs used for chronic disease management on Susceptibility and Severity of COVID-19: A Large Case-Control Study.
Cystic Fibrosis
Alterations in specific activity of lysosomal alpha-glucosidase in cystic fibrosis.
Dehydration
Postharvest ethylene treatment affects berry dehydration, polyphenol and anthocyanin content by increasing the activity of cell wall enzymes in Aleatico wine grape
Dementia
Cognitive and Antipsychotic Medication Use in Monoallelic GBA-Related Parkinson Disease.
Dementia
Glucocerebrosidase Deficiency in Drosophila Results in ?-Synuclein-Independent Protein Aggregation and Neurodegeneration.
Dementia
Glucocerebrosidase reduces the spread of protein aggregation in a Drosophila melanogaster model of neurodegeneration by regulating proteins trafficked by extracellular vesicles.
Dengue
Antiviral activities of sulfonium-ion glucosidase inhibitors and 5-thiomannosylamine disaccharide derivatives against dengue virus.
Diabetes Mellitus
A case of nephrogenic diabetes insipidus caused by obstructive uropathy due to prostate cancer.
Diabetes Mellitus
Antidiabetic potential of Asparagus racemosus Willd leaf extracts through inhibition of ?-amylase and ?-glucosidase.
Diabetes Mellitus
Antidiabetic potential of polyoxotungstates: in vitro and in vivo studies.
Diabetes Mellitus
Chickpea (Cicer arietinum L.) Lectin Exhibit Inhibition of ACE-I, ?-amylase and ?-glucosidase Activity.
Diabetes Mellitus
Food-grade mulberry powder enriched with 1-deoxynojirimycin suppresses the elevation of postprandial blood glucose in humans.
Diabetes Mellitus
Long-term treatment in diabetics with acarbose, a glucosidase inhibitor: efficacy, tolerability and effect on GI hormones.
Diabetes Mellitus
Reappraisal and perspectives of clinical drug-drug interaction potential of ?-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus.
Diabetes Mellitus
Sitagliptin but not alpha glucosidase inhibitor reduced the serum soluble CD163, a marker for activated macrophage, in individuals with type 2 diabetes mellitus.
Diabetes Mellitus
The effect of new alpha-glucosidase inhibitors (BAY m 1099 and BAY o 1248) on meal-stimulated increases in glucose and insulin levels in man.
Diabetes Mellitus
[Acarbose, a glucosidase inhibitor: a new therapeutic principle in diabetes mellitus]
Diabetes Mellitus
[Clinical experience with an alpha glucosidase inhibitor (acarbose) in the treatment of non-insulin-dependent diabetes. Multicenter study]
Diabetes Mellitus, Type 2
Alpha glucosidase inhibition in the treatment of non-insulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 2
Antidiabetic potential of Asparagus racemosus Willd leaf extracts through inhibition of ?-amylase and ?-glucosidase.
Diabetes Mellitus, Type 2
Change of Oral to Topical Corticosteroid Therapy Exacerbated Glucose Tolerance in a Patient with Plaque Psoriasis.
Diabetes Mellitus, Type 2
Chemometrics Optimized Extraction Procedures, Phytosynergistic Blending and in vitro Screening of Natural Enzyme Inhibitors Amongst Leaves of Tulsi, Banyan and Jamun.
Diabetes Mellitus, Type 2
Comparison of Placebo Effect between Asian and Caucasian Type 2 Diabetic Patients: A Meta-Analysis.
Diabetes Mellitus, Type 2
Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial.
Diabetes Mellitus, Type 2
Comparisons of the efficacy of alpha glucosidase inhibitors on type 2 diabetes patients between Asian and Caucasian.
Diabetes Mellitus, Type 2
DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.
Diabetes Mellitus, Type 2
Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes.
Diabetes Mellitus, Type 2
Kinetics of ?-glucosidase inhibition by different fractions of three species of Labiatae extracts: a new diabetes treatment model.
Diabetes Mellitus, Type 2
New glucosidase inhibitors from an ayurvedic herbal treatment for type 2 diabetes: structures and inhibition of human intestinal maltase-glucoamylase with compounds from Salacia reticulata.
Diabetes Mellitus, Type 2
Reappraisal and perspectives of clinical drug-drug interaction potential of ?-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Role of Drugs used for chronic disease management on Susceptibility and Severity of COVID-19: A Large Case-Control Study.
Diabetes Mellitus, Type 2
Sitagliptin but not alpha glucosidase inhibitor reduced the serum soluble CD163, a marker for activated macrophage, in individuals with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
The treatment of type 2 diabetes mellitus in youth : which therapies?
Diabetes Mellitus, Type 2
[Effect of glucosidase inhibitor, Bay g 5421 (acarbose), on the blood glucose in obese diabetic patients ty pe 2 (NIDDM) (author's transl)]
Gaucher Disease
Beta-glucosidase activity in liver, spleen and brain in acute neuropathic Gaucher disease.
Gaucher Disease
Celastrol increases glucocerebrosidase activity in Gaucher disease by modulating molecular chaperones.
Gaucher Disease
Clinicogenetic Profile, Treatment Modalities, and Mortality Predictors of Gaucher Disease: A 15-Year Retrospective Study.
Gaucher Disease
Gaucher disease in Syrian children: common mutations identification, and clinical futures.
Gaucher Disease
Gaucher disease type 1: Unexpected diagnosis in a 75-year old patient presenting with splenomegaly.
Gaucher Disease
Glucocerebrosidase Deficiency in Drosophila Results in ?-Synuclein-Independent Protein Aggregation and Neurodegeneration.
Gaucher Disease
Glucosidase acid beta gene mutations in Egyptian children with Gaucher disease and relation to disease phenotypes.
Gaucher Disease
Increased glucocerebrosidase expression and activity in preeclamptic placenta.
Gaucher Disease
Lentiviral Gene Therapy Using Cellular Promoters Cures Type 1 Gaucher Disease in Mice.
Gaucher Disease
Retroviral-mediated transfer of the human glucocerebrosidase gene into cultured Gaucher bone marrow.
Gaucher Disease
Three mutations of adult type 1 Gaucher disease found in a Chinese patient: A case report.
Gaucher Disease
[Gaucher's disease: results of enzymatic treatment with beta glucosidase acid]
Genetic Diseases, Inborn
Effects of lysosomal biotherapeutic recombinant protein expression on cell stress and protease and general host cell protein release in Chinese hamster ovary cells.
glucan 1,4-alpha-glucosidase deficiency
Juvenile acid maltase deficiency presenting as paravertebral pseudotumour.
glucan 1,4-alpha-glucosidase deficiency
Multiple muscles in the AMD quail can be "cross-corrected" of pathologic glycogen accumulation after intravenous injection of an [E1-, polymerase-] adenovirus vector encoding human acid-alpha-glucosidase.
Glucose Intolerance
DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.
Glucose Intolerance
SGLT2 inhibition alleviated hyperglycemia, glucose intolerance, and dumping syndrome-like symptoms in a patient with glycogen storage disease type Ia: a case report.
Glycogen Storage Disease
Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for glycogen storage disease type III.
Glycogen Storage Disease
Auditory system involvement in late onset Pompe disease: A study of 20 Italian patients.
Glycogen Storage Disease
Correction of glycogen storage disease type II by enzyme replacement with a recombinant human acid maltase produced by over-expression in a CHO-DHFR(neg) cell line.
Glycogen Storage Disease
Exercise, nutrition and enzyme replacement therapy are efficacious in adult Pompe patients: report from EPOC Consortium.
Glycogen Storage Disease
Extensive genetic heterogeneity in patients with acid alpha glucosidase deficiency as detected by abnormalities of DNA and mRNA.
Glycogen Storage Disease
Hyaluronidase increases the biodistribution of acid alpha-1,4 glucosidase in the muscle of Pompe disease mice: an approach to enhance the efficacy of enzyme replacement therapy.
Glycogen Storage Disease
Identification of a missense mutation in an adult-onset patient with glycogenosis type II expressing only one allele.
Glycogen Storage Disease
Identification of a missense mutation in one allele of a patient with Pompe disease, and use of endonuclease digestion of PCR-amplified RNA to demonstrate lack of mRNA expression from the second allele.
Glycogen Storage Disease
Identification of four novel mutations in the alpha glucosidase gene in five Italian patients with infantile onset glycogen storage disease type II.
Glycogen Storage Disease
Identification of the promoter region and gene expression for human acid alpha glucosidase.
Glycogen Storage Disease
Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model.
Glycogen Storage Disease
Isolation and partial characterization of the structural gene for human acid alpha glucosidase.
Glycogen Storage Disease
Juvenile acid maltase deficiency presenting as paravertebral pseudotumour.
Glycogen Storage Disease
Late familial pseudo-myopathic muscular glycogenosis with alpha 1,4 glucosidase deficiency. Morphological, histoenzymological and biochemical approach.
Glycogen Storage Disease
Late Onset Glycogen Storage Disease Type II: Pitfalls in the Diagnosis.
Glycogen Storage Disease
Molecular features of 23 patients with glycogen storage disease type III in Turkey: a novel mutation p.R1147G associated with isolated glucosidase deficiency, along with 9 AGL mutations.
Glycogen Storage Disease
Production of a Functional Human Acid Maltase in Tobacco Seeds: Biochemical Analysis, Uptake by Human GSDII Cells, and In Vivo Studies in GAA Knockout Mice.
Glycogen Storage Disease
Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: from our experience of 4 cases including an autopsy case.
Glycogen Storage Disease
Swiss national guideline for reimbursement of enzyme replacement therapy in late-onset Pompe disease.
Glycogen Storage Disease
The brain in late-onset glycogenosis II: a structural and functional MRI study.
Glycogen Storage Disease
The identification of five novel mutations in the lysosomal acid a-(1-4) glucosidase gene from patients with glycogen storage disease type II. Mutations in brief no. 134. Online.
Glycogen Storage Disease
[Clinical observation on human alpha glucosidase in treatment of five patients with glycogen storage disease ?].
Glycogen Storage Disease Type II
A randomized study of alglucosidase alfa in late-onset Pompe's disease.
Glycogen Storage Disease Type II
A severe form of non-classic Pompe's disease with normal creatinine kinase level.
Glycogen Storage Disease Type II
AAV Gene Therapy Utilizing Glycosylation-Independent Lysosomal Targeting Tagged GAA in the Hypoglossal Motor System of Pompe Mice.
Glycogen Storage Disease Type II
Absolute quantification of the total and antidrug antibody-bound concentrations of recombinant human ?-glucosidase in human plasma using protein G extraction and LC-MS/MS.
Glycogen Storage Disease Type II
Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for glycogen storage disease type III.
Glycogen Storage Disease Type II
Alpha Glucosidase Assay on Dried Blood Spot in the Early Diagnosis of Infantile Pompe Disease.
Glycogen Storage Disease Type II
An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond.
Glycogen Storage Disease Type II
Apical Hypertrophic Cardiomyopathy in an Infant: First Presentation of Pompe's Disease.
Glycogen Storage Disease Type II
Auditory system involvement in late onset Pompe disease: A study of 20 Italian patients.
Glycogen Storage Disease Type II
Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort.
Glycogen Storage Disease Type II
Correction of glycogen storage disease type II by enzyme replacement with a recombinant human acid maltase produced by over-expression in a CHO-DHFR(neg) cell line.
Glycogen Storage Disease Type II
Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors.
Glycogen Storage Disease Type II
Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.
Glycogen Storage Disease Type II
Deferoxamine mesylate improves splicing and GAA activity of the common c.-32-13T>G allele in late-onset PD patient fibroblasts.
Glycogen Storage Disease Type II
Deficiency of acid alpha glucosidase in the urine of patients with Pompe's disease.
Glycogen Storage Disease Type II
Desensitization of two young patients with infantile-onset Pompe disease and severe reactions to alglucosidase alfa.
Glycogen Storage Disease Type II
Diagnostic challenges for Pompe disease: an under-recognized cause of floppy baby syndrome.
Glycogen Storage Disease Type II
Effect of enzyme replacement therapy in late onset Pompe disease: open pilot study of 48 weeks follow-up.
Glycogen Storage Disease Type II
Effects of lysosomal biotherapeutic recombinant protein expression on cell stress and protease and general host cell protein release in Chinese hamster ovary cells.
Glycogen Storage Disease Type II
Exercise, nutrition and enzyme replacement therapy are efficacious in adult Pompe patients: report from EPOC Consortium.
Glycogen Storage Disease Type II
Extensive genetic heterogeneity in patients with acid alpha glucosidase deficiency as detected by abnormalities of DNA and mRNA.
Glycogen Storage Disease Type II
GENERALIZED GLYCOGENOSIS. REPORT OF A CASE WITH DEFICIENCY OF ALPHA GLUCOSIDASE.
Glycogen Storage Disease Type II
Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease.
Glycogen Storage Disease Type II
Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature.
Glycogen Storage Disease Type II
Hyaluronidase increases the biodistribution of acid alpha-1,4 glucosidase in the muscle of Pompe disease mice: an approach to enhance the efficacy of enzyme replacement therapy.
Glycogen Storage Disease Type II
Identification and characterization of aberrant GAA pre-mRNA splicing in pompe disease using a generic approach.
Glycogen Storage Disease Type II
Identification of a missense mutation in an adult-onset patient with glycogenosis type II expressing only one allele.
Glycogen Storage Disease Type II
Identification of a missense mutation in one allele of a patient with Pompe disease, and use of endonuclease digestion of PCR-amplified RNA to demonstrate lack of mRNA expression from the second allele.
Glycogen Storage Disease Type II
Identification of four novel mutations in the alpha glucosidase gene in five Italian patients with infantile onset glycogen storage disease type II.
Glycogen Storage Disease Type II
Identification of the promoter region and gene expression for human acid alpha glucosidase.
Glycogen Storage Disease Type II
Immunomodulatory, liver depot gene therapy for Pompe disease.
Glycogen Storage Disease Type II
Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model.
Glycogen Storage Disease Type II
Isolation and partial characterization of the structural gene for human acid alpha glucosidase.
Glycogen Storage Disease Type II
Juvenile acid maltase deficiency presenting as paravertebral pseudotumour.
Glycogen Storage Disease Type II
Late Onset Glycogen Storage Disease Type II: Pitfalls in the Diagnosis.
Glycogen Storage Disease Type II
Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients.
Glycogen Storage Disease Type II
Long-term follow-up results in enzyme replacement therapy for Pompe disease: a case report.
Glycogen Storage Disease Type II
Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker.
Glycogen Storage Disease Type II
Longitudinal follow-up to evaluate speech disorders in early-treated patients with infantile-onset Pompe disease.
Glycogen Storage Disease Type II
Mitochondrial Variants in Pompe Disease: A Comparison between Classic and Non-Classic Forms.
Glycogen Storage Disease Type II
Multiple muscles in the AMD quail can be "cross-corrected" of pathologic glycogen accumulation after intravenous injection of an [E1-, polymerase-] adenovirus vector encoding human acid-alpha-glucosidase.
Glycogen Storage Disease Type II
Next generation deep sequencing corrects diagnostic pitfalls of traditional molecular approach in a patient with prenatal onset of Pompe disease.
Glycogen Storage Disease Type II
Oral delivery of Acid Alpha Glucosidase epitopes expressed in plant chloroplasts suppresses antibody formation in treatment of Pompe mice.
Glycogen Storage Disease Type II
Peripheral nerve and neuromuscular junction pathology in Pompe disease.
Glycogen Storage Disease Type II
Phosphatidylserine Is Not Just a Cleanup Crew but Also a Well-Meaning Teacher.
Glycogen Storage Disease Type II
Production of a Functional Human Acid Maltase in Tobacco Seeds: Biochemical Analysis, Uptake by Human GSDII Cells, and In Vivo Studies in GAA Knockout Mice.
Glycogen Storage Disease Type II
Production of Human Acid-Alpha Glucosidase With a Paucimannose Structure by Glycoengineered Arabidopsis Cell Culture.
Glycogen Storage Disease Type II
Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: from our experience of 4 cases including an autopsy case.
Glycogen Storage Disease Type II
Quality of life and its contributors among adults with late-onset Pompe disease in China.
Glycogen Storage Disease Type II
Restoring the regenerative balance in neuromuscular disorders: satellite cell activation as therapeutic target in Pompe disease.
Glycogen Storage Disease Type II
Satellite cells maintain regenerative capacity but fail to repair disease-associated muscle damage in mice with Pompe disease.
Glycogen Storage Disease Type II
Suppression of autophagy in skeletal muscle uncovers the accumulation of ubiquitinated proteins and their potential role in muscle damage in Pompe disease.
Glycogen Storage Disease Type II
Sustained Correction of Motoneuron Histopathology Following Intramuscular Delivery of AAV in Pompe Mice.
Glycogen Storage Disease Type II
Swiss national guideline for reimbursement of enzyme replacement therapy in late-onset Pompe disease.
Glycogen Storage Disease Type II
Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease.
Glycogen Storage Disease Type II
The brain in late-onset glycogenosis II: a structural and functional MRI study.
Glycogen Storage Disease Type II
The identification of five novel mutations in the lysosomal acid a-(1-4) glucosidase gene from patients with glycogen storage disease type II. Mutations in brief no. 134. Online.
Glycogen Storage Disease Type II
Therapeutic Benefit of Autophagy Modulation in Pompe Disease.
Glycogen Storage Disease Type II
When more is less: excess and deficiency of autophagy coexist in skeletal muscle in Pompe disease.
Glycogen Storage Disease Type II
[Chronic respiratory failure in a case with juvenile-onset acid alpha-glucosidase deficiency; successful therapy with nasal intermittent positive pressure ventilation (NIPPV)]
Glycogen Storage Disease Type II
[Pompe disease is a differential diagnosis in case of reduced physical capacity and abnormal muscular fatigue.]
Glycogen Storage Disease Type III
Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for glycogen storage disease type III.
Glycogen Storage Disease Type III
Molecular features of 23 patients with glycogen storage disease type III in Turkey: a novel mutation p.R1147G associated with isolated glucosidase deficiency, along with 9 AGL mutations.
Hepatitis
Glucosidase inhibition enhances presentation of de-N-glycosylated hepatitis B virus epitopes by major histocompatibility complex class I in vitro and in woodchucks.
Hepatitis
Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents.
Hepatitis
Iminosugars as possible broad spectrum anti hepatitis virus agents: the glucovirs and alkovirs.
Hepatitis B
alpha-Glucosidase inhibitors have a prolonged antiviral effect against hepatitis B virus through the sustained inhibition of the large and middle envelope glycoproteins.
Hepatitis B
Glucosidase inhibition enhances presentation of de-N-glycosylated hepatitis B virus epitopes by major histocompatibility complex class I in vitro and in woodchucks.
Hepatitis B
Hepatitis B virus large and middle glycoproteins are degraded by a proteasome pathway in glucosidase-inhibited cells but not in cells with functional glucosidase enzyme.
Hepatitis B
Hepatitis B virus MHBs antigen is selectively sensitive to glucosidase-mediated processing in the endoplasmic reticulum.
Hepatitis B
Iminosugars as possible broad spectrum anti hepatitis virus agents: the glucovirs and alkovirs.
Hepatitis C
Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents.
Hepatitis C
Iminosugars as possible broad spectrum anti hepatitis virus agents: the glucovirs and alkovirs.
Hepatitis C
Reduction of the infectivity of hepatitis C virus pseudoparticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors.
Hepatitis C, Chronic
Inhibitors of endoplasmic reticulum alpha-glucosidases potently suppress hepatitis C virus virion assembly and release.
Hyperglycemia
Antidiabetic potential of Asparagus racemosus Willd leaf extracts through inhibition of ?-amylase and ?-glucosidase.
Hyperglycemia
Antidiabetic property of Symplocos cochinchinensis is mediated by inhibition of alpha glucosidase and enhanced insulin sensitivity.
Hyperglycemia
Beneficial effect of flax seeds in streptozotocin (STZ) induced diabetic mice: isolation of active fraction having islet regenerative and glucosidase inhibitory properties.
Hyperglycemia
Chickpea (Cicer arietinum L.) Lectin Exhibit Inhibition of ACE-I, ?-amylase and ?-glucosidase Activity.
Hyperglycemia
DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.
Hyperglycemia
Effects of insulin and other antihyperglycemic agents on lipid profiles of patients with diabetes.
Hyperglycemia
Genetic engineering of Lactococcus lactis to produce an amylase inhibitor for development of an anti-diabetes biodrug.
Hyperglycemia
In-vitro ? amylase and glycosidase inhibitory effect of ethanolic extract of antiasthmatic drug - Shirishadi.
Hyperglycemia
Islet protective and insulin secretion property of Murraya koenigii and Ocimum tenuflorum in streptozotocin-induced diabetic mice.
Hyperglycemia
Recent Trends in Therapeutic Approaches for Diabetes Management: A Comprehensive Update.
Hyperglycemia
Seed Proteomic Profiles of Three Paeonia Varieties and Evaluation of Peony Seed Protein as a Food Product.
Hyperglycemia
The administration of nonmetabolizable glucose analogues fails to suppress the development of glycogen autophagy in newborn rat hepatocytes.
Hypersensitivity
Generation of transgenic rice with reduced content of major and novel high molecular weight allergens.
Hypoglycemia
Use of the alpha glucosidase inhibitor acarbose in patients with 'Middleton syndrome': normal gastric anatomy but with accelerated gastric emptying causing postprandial reactive hypoglycemia and diarrhea.
Infections
DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials.
Infections
Management of patients with neuromuscular disorders at the time of the SARS-CoV-2 pandemic.
Infections
Mechanism of action of N-butyl deoxynojirimycin in inhibiting HIV-1 infection and activity in combination with nucleoside analogs.
Infections
Seminal alpha-glucosidase activity as a marker of epididymal pathology in nonazoospermic men consulting for infertility.
Infections
Transcriptome Analysis of Apple Leaves in Response to Powdery Mildew (Podosphaera leucotricha) Infection.
Infertility
Seminal alpha-glucosidase activity as a marker of epididymal pathology in nonazoospermic men consulting for infertility.
Influenza, Human
Effect of glycosylation and glucose trimming inhibitors on the influenza A virus glycoproteins.
Insulin Resistance
A quick overview on some aspects of endocrinological and therapeutic effects of Berberis vulgaris L.
Insulin Resistance
Antidiabetic property of Symplocos cochinchinensis is mediated by inhibition of alpha glucosidase and enhanced insulin sensitivity.
Liver Cirrhosis
Effects of the glucosidase inhibitor acarbose in patients with liver cirrhosis.
Liver Diseases
A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation.
Liver Diseases
Mutations in GANAB, Encoding the Glucosidase II? Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease.
Lymphoma
Characterization of endomannosidase inhibitors and evaluation of their effect on N-linked oligosaccharide processing during glycoprotein biosynthesis.
Lymphoma
Characterization of the endomannosidase pathway for the processing of N-linked oligosaccharides in glucosidase II-deficient and parent mouse lymphoma cells.
Lymphoma
Gaucher disease type 1: Unexpected diagnosis in a 75-year old patient presenting with splenomegaly.
Lymphoma
N-linked oligosaccharide processing enzyme glucosidase II produces 1,5-anhydrofructose as a side product.
Lysosomal Storage Diseases
Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors.
Lysosomal Storage Diseases
Synthesis of novel mono and bis-indole conduritol derivatives and their ?/?-glycosidase inhibitory effects.
Melanoma
Effect of inhibitors of N-linked oligosaccharide processing on the cell surface expression of a melanoma integrin.
Melanoma
Post-translational addition of chondroitin sulfate glycosaminoglycans. Role of N-linked oligosaccharide addition, trimming, and processing.
Melanoma
Rapid and reversible inhibition of tyrosinase activity by glucosidase inhibitors in human melanoma cells.
Metabolic Syndrome
In vitro Antioxidant, Anti-inflammatory, Anti-metabolic Syndrome, Antimicrobial, and Anticancer Effect of Phenolic Acids Isolated from Fresh Lovage Leaves [Levisticum officinale Koch] Elicited with Jasmonic Acid and Yeast Extract.
Muscular Diseases
Desensitization of two young patients with infantile-onset Pompe disease and severe reactions to alglucosidase alfa.
Muscular Diseases
Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature.
Muscular Diseases
Identification of patients with Pompé disease using routine pathology results: PATHFINDER (creatine kinase) study.
Muscular Diseases
Long-term follow-up results in enzyme replacement therapy for Pompe disease: a case report.
Muscular Diseases
Restoring the regenerative balance in neuromuscular disorders: satellite cell activation as therapeutic target in Pompe disease.
Muscular Diseases
Satellite cells maintain regenerative capacity but fail to repair disease-associated muscle damage in mice with Pompe disease.
Muscular Diseases
[Pompe disease is a differential diagnosis in case of reduced physical capacity and abnormal muscular fatigue.]
Muscular Dystrophies
Juvenile acid maltase deficiency presenting as paravertebral pseudotumour.
Neoplasms
A Diabetes Pay-for-Performance Program and Risks of Cancer Incidence and Death in Patients With Type 2 Diabetes in Taiwan.
Neoplasms
Changes in the activities of jejunal glucosidases in experimental intestinal tumorigenesis induced by 1,2 dimethylhydrazine in rats fed different diets.
Neoplasms
Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies.
Neoplasms
Synthesis of novel mono and bis-indole conduritol derivatives and their ?/?-glycosidase inhibitory effects.
Neoplasms
The alpha-glucosidase I inhibitor castanospermine alters endothelial cell glycosylation, prevents angiogenesis, and inhibits tumor growth.
Neuroblastoma
Uptake by neuroblastoma cells of glucosylceramide, glucosylceramide glucosidase, its stimulator protein, and phosphatidylserine.
Neurodegenerative Diseases
Functional Foods and Nutraceuticals as Dietary Intervention in Chronic Diseases; Novel Perspectives for Health Promotion and Disease Prevention.
Obesity
Effects of a glucosidase inhibitor (acarbose, BAY g 5421) on the development of obesity and food motivated behavior in Zucker (fafa) rats.
Obesity
Glucosidase inhibition. A new approach to the treatment of diabetes, obesity, and hyperlipoproteinaemia.
Obesity
Miglitol prevents diet-induced obesity by stimulating brown adipose tissue and energy expenditure independent of preventing the digestion of carbohydrates.
Overweight
Baseline Body Mass Index and the Efficacy of Hypoglycemic Treatment in Type 2 Diabetes: A Meta-Analysis.
Parkinson Disease
Cognitive and Antipsychotic Medication Use in Monoallelic GBA-Related Parkinson Disease.
Parkinson Disease
GBA-Associated Parkinson's Disease: Progression in a Deep Brain Stimulation Cohort.
Parkinson Disease
Glucocerebrosidase Deficiency in Drosophila Results in ?-Synuclein-Independent Protein Aggregation and Neurodegeneration.
Parkinsonian Disorders
Increased glucocerebrosidase expression and activity in preeclamptic placenta.
Polycystic Kidney Diseases
A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation.
Polycystic Kidney Diseases
Mutations in GANAB, Encoding the Glucosidase II? Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease.
Polyuria
A case of nephrogenic diabetes insipidus caused by obstructive uropathy due to prostate cancer.
Premature Ejaculation
[Semen biochemical markers and their significance in the patients with premature ejaculation]
pullulanase deficiency
Glycogen storage disease type III (glycogen debranching enzyme deficiency): correlation of biochemical defects with myopathy and cardiomyopathy.
Respiratory Insufficiency
[Chronic respiratory failure in a case with juvenile-onset acid alpha-glucosidase deficiency; successful therapy with nasal intermittent positive pressure ventilation (NIPPV)]
Speech Disorders
Longitudinal follow-up to evaluate speech disorders in early-treated patients with infantile-onset Pompe disease.
Teratocarcinoma
Transfer of nonglucosylated oligosaccharide from lipid to protein in a mammalian cell.
Thymoma
Unique expression of major histocompatibility complex class I proteins in the absence of glucose trimming and calnexin association.
Urticaria
Influence of Nesting Habitats on the Gut Enzymes Activity and Heavy Metal Composition of Apis mellifera andersonii L. (Hymenoptera: Apidae)
Vaccinia
Effect of a glucosidase inhibitor on the bioactivity and immunoreactivity of human immunodeficiency virus type 1 envelope glycoprotein.
Varicocele
Markers of accessory sex glands function in men with varicocele, relationship with seminal parameters.
Virus Diseases
Synthesis of novel mono and bis-indole conduritol derivatives and their ?/?-glycosidase inhibitory effects.
html completed